BIOGY
Price
$11.00
Change
+$0.65 (+6.28%)
Updated
Dec 23 closing price
Capitalization
1.22B
Intraday BUY SELL Signals
CAIHF
Price
Loading...
Change
-$0.00 (-0.00%)
Updated
Loading...
Capitalization
210.12M
Intraday BUY SELL Signals
Interact to see
Advertisement

BIOGY vs CAIHF

Header iconBIOGY vs CAIHF Comparison
Open Charts BIOGY vs CAIHFBanner chart's image
Biogaia AB
Price$11.00
Change+$0.65 (+6.28%)
Volume$1K
Capitalization1.22B
Chia Tai Enterprises International
PriceLoading...
Change-$0.00 (-0.00%)
Volume$510
Capitalization210.12M
BIOGY vs CAIHF Comparison Chart in %
BIOGY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BIOGY vs. CAIHF commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOGY is a Hold and CAIHF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (BIOGY: $11.00 vs. CAIHF: $0.28)
Brand notoriety: BIOGY and CAIHF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BIOGY: 100% vs. CAIHF: 100%
Market capitalization -- BIOGY: $1.22B vs. CAIHF: $210.12M
BIOGY [@Pharmaceuticals: Generic] is valued at $1.22B. CAIHF’s [@Pharmaceuticals: Generic] market capitalization is $210.12M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.17B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIOGY’s FA Score shows that 1 FA rating(s) are green whileCAIHF’s FA Score has 1 green FA rating(s).

  • BIOGY’s FA Score: 1 green, 4 red.
  • CAIHF’s FA Score: 1 green, 4 red.
According to our system of comparison, BIOGY is a better buy in the long-term than CAIHF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOGY’s TA Score shows that 4 TA indicator(s) are bullish.

  • BIOGY’s TA Score: 4 bullish, 1 bearish.

Price Growth

BIOGY (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while CAIHF (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.05%. For the same industry, the average monthly price growth was +6.84%, and the average quarterly price growth was +19.33%.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.05% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BIOGY($1.22B) has a higher market cap than CAIHF($210M). BIOGY has higher P/E ratio than CAIHF: BIOGY (32.54) vs CAIHF (2.72). BIOGY (0.000) and CAIHF (0.000) have similar YTD gains . BIOGY has higher annual earnings (EBITDA): 406M vs. CAIHF (6.29M). BIOGY has more cash in the bank: 728M vs. CAIHF (13.1M). BIOGY has higher revenues than CAIHF: BIOGY (1.46B) vs CAIHF (199M).
BIOGYCAIHFBIOGY / CAIHF
Capitalization1.22B210M580%
EBITDA406M6.29M6,458%
Gain YTD0.0000.000-
P/E Ratio32.542.721,198%
Revenue1.46B199M735%
Total Cash728M13.1M5,557%
Total DebtN/A78.2M-
FUNDAMENTALS RATINGS
BIOGY vs CAIHF: Fundamental Ratings
BIOGY
CAIHF
OUTLOOK RATING
1..100
4735
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
52
Fair valued
PROFIT vs RISK RATING
1..100
7964
SMR RATING
1..100
4289
PRICE GROWTH RATING
1..100
5034
P/E GROWTH RATING
1..100
563
SEASONALITY SCORE
1..100
n/a30

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIOGY's Valuation (6) in the null industry is somewhat better than the same rating for CAIHF (52). This means that BIOGY’s stock grew somewhat faster than CAIHF’s over the last 12 months.

CAIHF's Profit vs Risk Rating (64) in the null industry is in the same range as BIOGY (79). This means that CAIHF’s stock grew similarly to BIOGY’s over the last 12 months.

BIOGY's SMR Rating (42) in the null industry is somewhat better than the same rating for CAIHF (89). This means that BIOGY’s stock grew somewhat faster than CAIHF’s over the last 12 months.

CAIHF's Price Growth Rating (34) in the null industry is in the same range as BIOGY (50). This means that CAIHF’s stock grew similarly to BIOGY’s over the last 12 months.

CAIHF's P/E Growth Rating (3) in the null industry is somewhat better than the same rating for BIOGY (56). This means that CAIHF’s stock grew somewhat faster than BIOGY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOGYCAIHF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
34%
N/A
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
28%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
36%
Bullish Trend 2 days ago
5%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
32%
Bullish Trend 2 days ago
4%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
44%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BIOGY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UBVSX81.560.68
+0.84%
Undiscovered Managers Behavioral Val I
WGLSX12.910.08
+0.62%
Wasatch Long/Short Alpha Institutional
NBNCX15.210.05
+0.33%
Neuberger International Sel C
FTINX12.95N/A
N/A
Fidelity Advisor Asset Manager 30% I
EGORX19.78-0.18
-0.90%
Allspring Large Cap Core R6

BIOGY and

Correlation & Price change

A.I.dvisor tells us that BIOGY and BIOVF have been poorly correlated (+11% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOGY and BIOVF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOGY
1D Price
Change %
BIOGY100%
N/A
BIOVF - BIOGY
11%
Poorly correlated
+1.13%
ARSUF - BIOGY
2%
Poorly correlated
N/A
BKUH - BIOGY
1%
Poorly correlated
N/A
CANN - BIOGY
-0%
Poorly correlated
-5.15%
CAIHF - BIOGY
-0%
Poorly correlated
N/A
More